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ABSTRACT 
 
Background Oral anticoagulation is highly effective preventing stroke and 
mortality in non-valvular atrial fibrillation patients. However, the efficacy and safety 
of vitamin K antagonists, the main oral anticoagulation drug used) strongly depends 
upon the quantity of anticoagulation control, as reflected by the average 
percentage of the time in therapeutic range of INR (International Normalised Ratio) 
2.0-3.0.  An easy, simple prediction of which atrial fibrillation patients are likely to 
do well on vitamin K antagonists (with good average time in therapeutic range) 
could guide decision-making between using vitamin K antagonists (eg. warfarin) and 
non-vitamin K antagonist oral anticoagulants (NOACs). 
Methods and Results In a consecutive cohort of non-valvular atrial fibrillation 
patients attending our anticoagulation clinic, we tested the hypothesis that the new 
SAME-TT2R2 score was a predictor for good average time in therapeutic range, and 
second, this would translate into adverse events in a ‘real world’ cohort of patients 
with non-valvular atrial fibrillation. 
The incidence of both bleeding, adverse cardiovascular events (including 
stroke/thromboembolism) and mortality during the follow-up was higher with 
increasing SAME-TT2R2 score. The SAME-TT2R2 score was predictive for the 
composite of all adverse events [Hazard Ratio: 1.32 (1.17-1.50); p<0.001], adverse 
cardiovascular events [1.52 (1.28-1.83); p<0.001], and all-cause mortality [1.41 
(1.16-1.67); p=0.001]. A trend was also observed for major bleeding events [1.23 
(0.99-1.53); p=0.059]. 
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Conclusion In a ‘real world’ cohort of consecutive patients with non-valvular 
atrial fibrillation, a high SAME-TT2R2 score (reflecting poor anticoagulation control 
with poor time in therapeutic range) was associated with more bleeding, adverse 
cardiovascular events and mortality during follow-up.   
 
Key words: SAME-TT2R2 score, atrial fibrillation, anticoagulation, stroke, bleeding, 
mortality 
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INTRODUCTION 
Oral anticoagulation is highly effective preventing stroke and mortality in non-
valvular atrial fibrillation patients[1]. However, the efficacy and safety of vitamin K 
antagonists depends upon the quality of anticoagulant control, as reflected by the 
average percentage of the time in therapeutic range of INR 2.0-3.0.  Various studies 
have shown how a high time in therapeutic range translates into a lower risk of 
stroke and bleeding, whilst on oral anticoagulation [2-4].  A recent European 
consensus document recommends that an average individual time in therapeutic 
range should be >70% for optimal efficacy and safety outcomes whilst on a vitamin 
K antagonists and this is also recommended in international guidelines [5]. The 
vitamin K antagonists were the main oral anticoagulant drug used until the 
introduction of the non-vitamin K antagonist oral anticoagulants (NOACs, previously 
referred to as novel or new oral anticoagulants). 
The difficulties in achieving a high time in therapeutic range as well as the 
inconvenience of regular anticoagulation monitoring and the various food/drug 
restrictions associated with the vitamin K antagonists have led to the recent 
introduction of the NOACs, which offer improved efficacy, safety and convenience 
compared to the vitamin K antagonists [5]. Even in clinical trials, patients in centres 
with high average time in therapeutic range have less marked difference in efficacy 
outcomes between NOACs and warfarin [6]. 
An easy, simple prediction of which atrial fibrillation patients are likely to do well on 
vitamin K antagonists (with good average time in therapeutic range) could guide 
decision-making between using vitamin K antagonists and NOACs. Recently, 
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Apostolakis et al [7] proposed and validated the SAME-TT2R2 score [Sex, Age (<60 
years), Medical history (at least 2 of the following: hypertension, diabetes, coronary 
artery disease/myocardial infarction, peripheral arterial disease, congestive heart 
failure, previous stroke, pulmonary disease, hepatic or renal disease), Treatment 
(interacting drugs eg amiodarone for rhythm control) [all 1 point], as well as current 
Tobacco use (2 points) and Race (non-Caucasian; 2 points)] (see Table 1).This simple 
score (SAMe-TT2R2) could help decision making by identifying those atrial fibrillation 
patients that would do well on vitamin K antagonists (with a high average time in 
therapeutic range, with SAMe-TT2R2 score=0-1), or conversely, those likely to have 
anticoagulation control (ie. poor average time in therapeutic range, with SAMe-
TT2R2 score ≥2) who require additional interventions to achieve acceptable 
anticoagulation control or be candidates for NOACs. This score was derived from 
the AFFIRM (Atrial Fibrillation Followup Investigation of Rhythm Management) trial 
population and externally validated in a small ‘real world’ cohort of anticoagulated 
non-valvular atrial fibrillation patients[7].  Further validations in large ‘real world’ 
cohorts are necessary, also to assess whether this score (which reflects time in 
therapeutic range) translates into adverse outcomes in anticoagulated non-valvular 
atrial fibrillation patients. 
In a consecutive cohort of non-valvular atrial fibrillation patients attending our 
anticoagulation clinic, we tested the hypothesis that new SAME-TT2R2 score as a 
predictor for average time in therapeutic range. Second, we investigated whether 
the latter translated into adverse events (major bleeding, adverse cardiovascular 
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events, mortality) in our ‘real world’ cohort of patients with non-valvular atrial 
fibrillation. 
 
METHODS 
We recruited consecutive patients with permanent or paroxysmal atrial fibrillation on 
a vitamin K antagonist from our outpatient anticoagulation clinic. In order to 
homogenize the baseline cohort of patients, only patients who had an International 
Normalised Ratio between 2.0 and 3.0 during the previous 6 months were included. 
Patients with prosthetic heart valves or valvular atrial fibrillation were excluded from 
the study, as well as those presenting acute coronary syndrome, stroke (ischaemic or 
embolic), any haemodynamic instability or hospital admission or surgical intervention 
in the preceding 6 months. A history of malignancy was allowed if the patient’s 
expected survival duration was more than 6 months and not receiving chemotherapy 
or radiotherapy at study entry. A complete medical history was recorded at inclusion. 
Follow-up was performed through visits to the anticoagulation clinic, the hospital 
electronic medical records system or, when unavailable or persisting doubts, by 
telephone interview.  
Baseline stroke risk was assessed using the CHA2DS2-VASc [Cardiac failure or 
dysfunction, Hypertension, Age over 75 years [Doubled], Diabetes, Stroke [Doubled] – 
Vascular disease, Age between 65-74 and Sex category [Female]) score, as described in 
recent guidelines [5;8]. The HAS-BLED bleeding risk score was calculated as a measure 
of baseline bleeding risk, as the result of adding one point to Hypertension, Abnormal 
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renal/liver function (one point each), Stroke, Bleeding history or predisposition, Labile 
International Normalised Ratio(INR), Elderly (age over 65) and Drugs/alcohol 
concomitantly (one point for each one) [9]. 
Adverse cardiovascular end-points (mainly thromboembolic) were defined as 
stroke/transient ischemic attack, peripheral embolism, acute coronary syndrome, 
acute heart failure and cardiac death. Bleeding events were assessed by the 2005 
International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal 
bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular 
with compartment syndrome, and/or bleeding causing a fall in haemoglobin level of 20 
g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole 
blood or red cells[10]. Finally, we recorded all-cause mortality, and whether the cause 
of death was secondary to a cardiovascular event (stroke/ transient ischemic attack, 
peripheral embolism, acute coronary syndrome, acute heart failure and cardiac death) 
or a haemorrhagic one.  At six months after inclusion, we calculated the percentage of 
International Normalised Ratio measures within the therapeutic range during the 
previous 6 months, as an estimation of the time in therapeutic range.  
The protocol study was approved by the Ethical Committee from University Hospital 
Morales Meseguer, and patients gave informed consent to participation in the study. 
Statistical analysis  
Continuous variables were tested for normality by the Kolmogorov-Smirnov test. 
Continuous variables are presented as a mean ± standard deviation (SD) or median 
(interquartile range, IQR), as appropriate, and categorical variables as a percentage. 
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Cox models were used to determine the association between clinical risk factors and 
bleeding, as well as cardiovascular events and mortality. The independent effect of 
clinical variables on prognosis was calculated using a Cox proportional hazard 
regression model, and analysis of variance (ANOVA) models were used to compare 
means between different groups. The c-statistic was calculated using ROC curves. A 
p<0.05 was accepted as statistically significant. Statistical analyses were performed 
using SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL, USA). 
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RESULTS 
We studied 972 patients (49% male, median age 76 years [interquartile range (IQR) 70-
80] [Table 2]. The median CHA2DS2-VASc score was 4 (IQR 3-5) and 93% had a CHA2DS2-
VASc score ≥2. The median HAS-BLED score was 2 (IQR 2-3).  
Median follow-up was 952 (784-1078) days, and during this period, 107 patients had 
an adverse cardiovascular event (4.22%/year): of these35 were strokes (1.38%/year), 
42 were acute coronary syndrome events (1.65%/year) and 31 acute heart failure 
events (1.22%/year). Of the cohort, 77 patients presented with a major bleeding 
(3.04%/year) and 91 patients died (3.59%/year).  In the following 6 months after 
inclusion, mean time in therapeutic range was 78.0±19.98%. 
Predictive value for anticoagulation control 
In our anticoagulated patients, increasing baseline SAME-TT2R2 score was associated 
with significantly lower mean time in therapeutic range at 6 months after inclusion. 
This ranged from 79.7% for patients with SAME-TT2R2score of 0 points to 72.3% for 
patients with 5 points (p=0.043) [Table 3]. 
Predictive value of the SAME-TT2R2 score for bleeding, cardiovascular events and death 
The SAME-TT2R2 score had a c-statistic for adverse cardiovascular events of 0.62 
(95%CI 0.57-0.68; p<0.001); for bleeding, the c-statistic was 0.55 (95%CI 0.49-0.62; 
p=0.117).  For all-cause mortality, the c-statistic was 0.62 (95%CI 0.55-0.68; p<0.001).  
Major adverse events  
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The incidence of both adverse cardiovascular events (including stroke/ 
thromboembolism) and bleeding and mortality during the follow-up was higher with 
increasing SAME-TT2R2 score at baseline (Figure 1). 
On unadjusted (crude) analyses, the SAME-TT2R2 score was predictive for the 
composite of all adverse events [Hazard Ratio, HR: 1.32 (1.17-1.50); p<0.001], adverse 
cardiovascular events [HR 1.52 (1.28-1.83); p<0.001], and for all-cause mortality 
[1.41(1.16-1.71); p=0.001].  Only a non-significant trend was seen regarding major 
bleeding events [1.23 (0.99-1.53); p=0.059]. 
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Discussion 
In a ‘real world’ cohort of consecutive patients with non-valvular atrial fibrillation, 
we have shown that a low SAME-TT2R2 score was a significant predictor for good 
anticoagulation control (as reflected by time in therapeutic range).  A high SAME-
TT2R2 score (reflecting poor anticoagulation control with poor time in therapeutic 
range) translated into more bleeding, adverse cardiovascular events (including 
stroke/thromboembolism) and mortality during follow-up.  To the best of our 
knowledge, we have also validated the SAME-TT2R2 score for the first time in 
consecutive atrial fibrillation patients taking acenocoumarol treatment as their oral 
anticoagulant (rather than warfarin). 
Non-valvular atrial fibrillation patients are at high risk for cardiovascular events and 
mortality. Our population was an elderly cohort with non-valvular atrial fibrillation 
where over 50% were aged>75 years. Moreover, our population had an 
intermediate-high thrombotic risk and multiple prevalent comorbidities.  Even 
though patients with good drug compliance, various acute or clinical decompensate 
events may lead to unstable International Normalised Ratio control, and therefore, 
good prior International Normalised Ratio control does not necessarily imply good 
control in the future.  Also, the largest randomised trial of genotype-guided 
(pharmacogenetically based) dosing of warfarin did not result in improved 
anticoagulation control [11].  Thus, the ability to have a simple, practical way to 
predict who is likely to do well on vitamin K antagonists, or those less likely to have 
good anticoagulation control where NOACs would benefit could help decision 
making in everyday clinical practice [12, 13]. 
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International Normalised Ratio control and quality of anticoagulation is most often 
assessed by the time in therapeutic range. The average individual time in therapeutic 
range is known to increase over time, as more International Normalised Ratio 
fluctuations occur during the first 3 months following initiation of vitamin K 
antagonists [14]. Good adherence to the therapy, as well as minimising drug or diet 
interactions influences time in therapeutic range outcomes. In the present study, we 
selected experienced anticoagulated patients with excellent anticoagulation control at 
baseline to ensure some degree of patient homogeneity, and thus adherence to the 
therapy was expected to be high and not affect subsequent measurements. However, 
we found that the SAME-TT2R2 score was still able to predict which patients were 
prone to subsequent instability and poor International Normalised Ratio control, even 
among previously anticoagulated patients, with good time in therapeutic range at 
inclusion. Slight differences were observed, among the different range of SAME-TT2R2 
scores, due to our inclusion criteria, given that all patients had shown previously 
excellent International Normalised Ratio control.  
The SAME-TT2R2 score was found to be predictive for both adverse cardiovascular 
events and mortality, but only a trend was observed regarding major bleeding events. 
It should be beard in mind that the anticoagulation control in our cohort was optimal 
and therefore only few major bleeding events occurred during the follow-up (with a 
rate of 3%/year). 
Although the SAME-TT2R2 score at baseline is related to outcomes (mainly adverse 
cardiovascular events and mortality, but also to major bleeding), the low c-statistics 
show a moderate discriminatory ability of the survival model. This might be related to 
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low outcome event rates (manly few major bleeding events during the follow-up, with 
an annual rate of 3%/year), due to the good control of anticoagulation therapy in our 
(selected) cohort at baseline.  Given the modest discriminatory ability (as reflected by 
c-statistics) of the SAME-TT2R2 score in our well controlled anticoagulated clinic 
population, it is unclear how the score would perform in a less meticulously cared for 
group of patients.   
Of note, we studied a Caucasian population, without any prevalence of other ethnic 
races, which is one of the risk factors for poor time in therapeutic range, based on the 
SAME-TT2R2 score [7]. Thus, none of the patients could reach a AME-TT2R2 score of >6 
points. Moreover, high scores were poorly represented in our cohort, as only 6 
patients had a score of 5 and none has a score of 6, perhaps reflecting our selection 
criteria, as stable International Normalised Ratio was required at baseline. Indeed, 
patients with the highest SAME-TT2R2scores did not achieve good anticoagulation 
control and therefore were probably excluded from the present cohort.  
Limitations 
The possibility of some selection bias cannot be excluded as our patients were 
clinically stable at stable entry, so unstable patients who are more prone to have 
adverse events were excluded, unlike other clinical studies where patients recruited 
would present with a time in therapeutic range ranging from 60 to 75%. Similarly, we 
selected for our cohort ‘anticoagulation experienced’ patients with proven adherence 
and good anticoagulation control during 6 months prior to inclusion. Thus, patients 
with erratic anticoagulation (who would probably have higher SAME-TT2R2score 
values) were excluded from the analysis. This specific selection of patients (stable on 
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acenocumarol with high initial time in therapeutic range at entry) would perhaps limit 
the generalizability of our findings to less well-controlled populations.  Furthermore, 
we used acenocoumarol (the most widely used vitamin K antagonists in Spain), which 
differs from the warfarin with a shorter half-life, which is perceived to lead to more 
unstable anticoagulation, although no results comparing the different vitamin K 
antagonists have been published.  We also presumed that patients with high SAME-
TT2R2 score would be “suitable” to be treated with NOAC, but we have not studied 
such a population.  Finally, we studied a Caucasian population, without any other races 
being studied, and thus, further studies in ethnically diverse populations would be 
required.  Ongoing prospective studies will address all these aspects.   
In conclusion, a low SAME-TT2R2 score was a significant predictor for a good 
anticoagulation control (as reflected by time in therapeutic range), whilst a high SAME-
TT2R2 score (reflecting poor anticoagulation control) was associated with more 
bleeding, adverse cardiovascular events and mortality during follow-up. Thus, the 
simple SAME-TT2R2 score may aid decision-making by identifying those atrial 
fibrillation patients likely to do well on Vitamin K antagonist (score 0-2) or those likely 
to have poor(er) anticoagulation control (score >2) who could be better off being 
started on NOACs as initial therapy, or be ‘flagged up’ for more aggressive efforts to 
improve anticoagulation control.  
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Table 1. The SAME-TT2R2 score   
 
 
 
 
 
 
 
 
 
 
 
1
Defined as more than 2 of the following: hypertension, diabetes, coronary artery 
disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous 
stroke, pulmonary disease, hepatic or renal disease. 
S Sex (female) 1 
A Age (less than 60 years) 1 
M 
Medical history
1
 1 
e 
T Treatment (rhythm control strategy) 1 
T Tobacco use (within 2 years) 2 
R Race (non Caucasian) 2 
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Table 2.Baseline clinical characteristics 
 
Baseline characteristics N= 972 
Male sex 478 (49%) 
Age, median (IQR)  
Age < 60 
76 (70-80) 
66 (7%) 
Hypertension  796 (82%) 
Diabetes mellitus  249 (26%) 
Heart failure 350 (36%) 
History of stroke or TIA 182 (19%) 
Hepatic impairment  11 (1%) 
Renal impairment 94 (10%) 
Coronary artery disease 182 (19%) 
Hypercholesterolemia 303 (31%) 
Current smoking habit 136 (14%) 
Current alcoholic consumption 24 (2.5%) 
Previous bleeding episode 79 (8%) 
Concomitant malignant disease 58 (6%) 
Concomitant treatment 
Antiplatelet therapy 
Angiotensin-converting enzyme inhibitors 
 Angiotensin-renin blockers 
Calcium antagonist 
Beta-blockers 
Statins 
Digoxin 
Diuretics 
 
156 (16%) 
244 (25%) 
214 (22%) 
208 (21%) 
293 (30%) 
202 (21%) 
179 (18%) 
401 (41%) 
CHA2DS2-VASc score,  median (IQR) 4 (3-5) 
HAS-BLED score, median (IQR) 2 (2-3) 
SAME-TT2R2 score, median (IQR) 2 (1-2) 
 
CHA2DS2-VASc: Cardiac failure or dysfunction, Hypertension, Age ≥75[Doubled], 
Diabetes, Stroke[Doubled] – Vascular disease, Age 65-74 and Sex category [Female] 
HAS-BLED: Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or 
Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly 
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Table 3.Baseline SAME-TT2R2 
 
SAME-TT2R2 score score TTR at 6 months 
follow-up 
Mean (± standard 
deviation) 
N= 972 
• Low 0 – 1 79.67(± 19.46) 431 (44%) 
• Borderline 2 78.40 (±20.28) 332 (34%) 
• High ≥3 74.25 (±20.24) 208 (22%) 
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Figure 1. Adverse events according to SAME-TT2R2 score at baseline. 
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Clinical significance: 
• In a ‘real world’ cohort of consecutive patients with NVAF, a high SAME-TT2R2 score 
(reflecting poor anticoagulation control with poor time-in-therapeutic range (TTR)) 
was associated with more bleeding, adverse cardiovascular events and mortality 
during follow-up. 
• The SAME-TT2R2 score is an easy, simple prediction of which AF patients are likely 
to do well on VKA (with good average TTR) could guide decision-making between 
using VKAs and non-VKA oral anticoagulants (NOACs). 
 
